 |
 |
|
North East and North Cumbria
ICS Formulary |
| Formulary Chapter 4: Central nervous system - Full Section
|
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
04.01 |
Hypnotics and anxiolytics (0,0)
|
|
04.01.01 |
Hypnotics
(1,0)
|
|
|
Benzodiazepines
(1,0)
|
|
|
Zaleplon, Zolpidem and Zopiclone
(2,0)
|
|
|
Chloral and derivatives
(2,0)
|
|
|
Clomethiazole (Chlormethiazole)
(1,0)
|
|
|
Antihistamines
(1,0)
|
|
|
Daridorexant
(1,0)
|
|
|
Sodium oxybate
(1,0)
|
|
|
Pitolisant (0,0)
|
|
04.01.02 |
Anxiolytics
(1,0)
|
|
|
Benzodiazepines
(3,0)
|
|
|
Buspirone
(1,0)
|
|
|
Beta blockers (0,0)
|
|
|
Meprobamate (0,0)
|
|
04.01.03 |
Barbiturates (0,0)
|
|
04.02 |
Drugs used in psychoses and related disorders (0,0)
|
|
04.02.01 |
Antipsychotic Drugs
(1,0)
|
|
|
First Generation Antipsychotic Drugs
(8,0)
|
|
|
Second Generation Antipsychotic Drugs
(7,0)
|
|
04.02.02 |
Antipsychotic depot injections
(8,0)
|
|
04.02.03 |
Drugs used for mania and hypomania
(4,0)
|
|
|
Benzodiazepines (0,0)
|
|
|
Antipsychotic drugs (0,0)
|
|
|
Carbamazepine
(1,0)
|
|
|
Valproic acid
(2,0)
|
|
|
Lithium
(2,0)
|
|
04.03 |
Antidepressant drugs (0,0)
|
|
04.03.01 |
Tricyclic and related antidepressant drugs (0,0)
|
|
|
Tricyclic antidepressants
(4,0)
|
|
|
Related antidepressants
(1,0)
|
|
04.03.02 |
Monoamine-oxidase inhibitors
(1,0)
|
|
|
Reverible MAOIs
(1,0)
|
|
04.03.03 |
Selective serotonin re-uptake inhibitors
(5,0)
|
|
04.03.04 |
Other antidepressant drugs
(6,0)
|
|
04.04 |
CNS stimulants and other drugs used for attention deficit hyperactivity disorder
(8,0)
|
|
|
Cocaine (0,0)
|
|
04.05 |
Drugs used in the treatment of obesity (0,0)
|
|
04.05.01 |
Anti-obesity drugs acting on the gastro-intestinal tract
(2,0)
|
|
04.05.02 |
Centrally acting appetite suppressants (0,0)
|
|
04.06 |
Drugs used in nausea and vertigo
(5,0)
|
|
|
Vomiting during pregnancy (0,0)
|
|
|
Postoperative nausea and vomiting (0,0)
|
|
|
Motion sickness (0,0)
|
|
|
Other vestibular disorders (0,0)
|
|
|
Cytotoxic chemotherapy (0,0)
|
|
|
Palliative care (0,0)
|
|
|
Migraine (0,0)
|
|
|
Antihistamines
(3,0)
|
|
|
Phenothiazines and related drugs
(1,0)
|
|
|
Domperidone and metoclopramide
(2,0)
|
|
|
5HT3 antagonists
(3,0)
|
|
|
Neurokinin receptor antagonist
(2,0)
|
|
|
Cannabinoid
(1,0)
|
|
|
Hyoscine
(1,0)
|
|
|
Other drugs for Ménière's disease
(1,0)
|
|
04.07 |
Analgesics (0,0)
|
|
04.07.01 |
Non-opioid analgesics and compound analgesic preparations
(5,0)
|
|
|
Compound analgesic preparations (0,0)
|
|
04.07.02 |
Opioid analgesics
(14,0)
|
|
|
Weak opioids (0,0)
|
|
|
Strong opioids (0,0)
|
|
|
Breakthrough pain (0,0)
|
|
|
Injectable (0,0)
|
|
|
Other (0,0)
|
|
04.07.03 |
Neuropathic pain
(7,0)
|
|
|
Trigeminal neuralgia (0,0)
|
|
|
Postherpetic neuralgia
(2,0)
|
|
|
Chronic facial pain (0,0)
|
|
04.07.04 |
Antimigraine drugs (0,0)
|
|
04.07.04.01 |
Treatment of the acute migraine attack
(1,0)
|
|
|
Analgesics
(5,0)
|
|
|
5HT1 agonists
(3,0)
|
|
|
Ergot alkaloids (0,0)
|
|
|
Anti-emetics
(1,0)
|
|
|
Other drugs for migrane (0,0)
|
|
04.07.04.02 |
Prophylaxis of migraine
(14,0)
|
|
04.07.04.03 |
Cluster headache
(2,0)
|
|
04.08 |
Antiepileptics (0,0)
|
|
04.08.01 |
Control of epilepsy
(30,0)
|
|
|
Partial seizures with or without secondary generalisation (0,0)
|
|
|
Generalised seizures (0,0)
|
|
|
Carbamazepine and Oxcarbazepine (0,0)
|
|
|
Ethosuximide (0,0)
|
|
|
Gabapentin and pregabalin (0,0)
|
|
|
Lacosamide (0,0)
|
|
|
Lamotrigine (0,0)
|
|
|
Levetiracetam (0,0)
|
|
|
Perampanel (0,0)
|
|
|
Phenobarbital and other barbiturates (0,0)
|
|
|
Phenytoin (0,0)
|
|
|
Retigaine (0,0)
|
|
|
Rufinamide (0,0)
|
|
|
Rufinamide (0,0)
|
|
|
Tiagabine (0,0)
|
|
|
Topiramate (0,0)
|
|
|
Valproate (0,0)
|
|
|
Vigabatrin (0,0)
|
|
|
Zonisamide (0,0)
|
|
|
Benzodiazepines (0,0)
|
|
|
Other Drugs
(1,0)
|
|
04.08.02 |
Drugs used in status epilepticus
(7,0)
|
|
04.08.03 |
Febrile convulsions
(1,0)
|
|
04.09 |
Drugs used in parkinsonism and related disorders (0,0)
|
|
04.09.01 |
Dopaminergic drugs used in Parkinsons disease
(6,0)
|
|
|
Dopamine receptor agonists
(5,0)
|
|
|
Levodopa
(3,0)
|
|
|
Monoamine-oxidase-B inhibitors
(2,0)
|
|
|
Catachol-O-methyltransferase inhibitors
(3,0)
|
|
|
Amantadine
(1,0)
|
|
|
Mild to moderate dementia in Parkinsons disease (0,0)
|
|
04.09.02 |
Antimuscarinic drugs used in parkinsonism
(3,0)
|
|
04.09.03 |
Drugs used in essential tremor, chorea, tics, and related disorders
(8,0)
|
|
|
Torsion dystonias and other involuntary movements (0,0)
|
|
04.09.04 |
Restless leg syndrome (0,0)
|
|
04.10 |
Drugs used in substance dependence (0,0)
|
|
|
Alcohol dependence (0,0)
|
|
|
Cigarette smoking (0,0)
|
|
|
Opioid dependence (0,0)
|
|
04.10.01 |
Alcohol dependence
(5,0)
|
|
04.10.02 |
Nicotine dependence
(3,0)
|
|
04.10.03 |
Opioid dependence
(5,0)
|
|
|
Opioid substitution therapy
(1,0)
|
|
|
Adjunctive therapy and symptomatic treatment (0,0)
|
|
|
Opioid-receptor antagonists (0,0)
|
|
04.11 |
Drugs for dementia
(4,0)
|
|
04.12 |
Miscellaneous
(5,0)
|
|
|
|
